A multicenter, randomized, double-blind, placebo controlled, dose escalation study of the safety and efficacy of XTL 2125 in adult HCV-infected patients with compensated liver disease, who are interferon-alpha non-responders or have relapsed from interferon-alpha therapy
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2007
At a glance
- Drugs XTL 2125 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 05 Nov 2007 Status changed from initiated to withdrawn prior to recruitment.
- 12 Nov 2006 New trial record.